Result:Weak· Market: Down#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 2.79 | 19.2% | 3.7% |
| Total Income | 2.84 | 68.6% | 6.1% |
| Expenditure | 5.07 | 15.6% | 22.1% |
| PBT | -2.23 | 173.8% | 36.0% |
| Net Profit | -2.23 | 173.4% | 36.0% |
| OPM | -65.75% | 6.01pp | |
| NPM | -78.67% | 112.34pp | |
| EPS | 1.79 | 26.6% | 36.1% |
Pharma company still posting a loss with negative OPM/NPM despite narrowing YoY off a weak base and flat revenue growth, so the core business shows no real recovery.
Informational and educational content only. Not investment advice.